Avalyn Pharma (NASDAQ:AVLN) Rating Lowered to Sell at Wall Street Zen

Avalyn Pharma (NASDAQ:AVLN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

AVLN has been the topic of several other research reports. Weiss Ratings began coverage on shares of Avalyn Pharma in a report on Thursday. They issued a “sell (d+)” rating on the stock. Guggenheim started coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 target price for the company. Zacks Research raised Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Evercore started coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price target on the stock. Finally, Jefferies Financial Group started coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $52.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Avalyn Pharma Stock Performance

AVLN opened at $39.25 on Friday. The company’s 50-day moving average is $30.15. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.74 billion and a PE ratio of -1.80. Avalyn Pharma has a 52-week low of $24.15 and a 52-week high of $39.99.

Avalyn Pharma (NASDAQ:AVLN) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. Research analysts forecast that Avalyn Pharma will post -3.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Avalyn Pharma

A hedge fund recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp purchased a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN) during the second quarter, according to its most recent filing with the SEC. The firm purchased 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma at the end of the most recent quarter.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.